Bradykinin Induces Eosinophil Accumulation in the Rat Pleural Cavity

Authors:
  • MMMarco A. Martins
    Marco A. Martins
  • PSPatricia M.R. Silva
    Patricia M.R. Silva
  • HNHugo C. Castro Faria Neto
    Hugo C. Castro Faria Neto
  • APAna L.A. Pires
    Ana L.A. Pires
  • RCRenato S.B. Cordeiro
    Renato S.B. Cordeiro

Abstract
Intrathoracic injections of bradykinin (1–100 μg/cavity) induced a dose-dependent increase in the number of eosinophils recovered from the rat pleural cavity 24 h later. Eosinophilia by bradykinin was preceded by a marked pleural neutrophil influx within 6 h and was absent only 72 h following stimulation. Bradykinin (10––9––10––5M) failed to induce in vitro eosinophil chemotaxis, indicating that its in vivo effect must be mediated by an intermediate messenger. BW 755C (25 mg/kg) and the more selective lipoxygenase inhibitor BW A4C (20 μg/cavity) suppressed the pleural eosinophilia induced by bradykinin (50 μg/cavity), whereas the platelet-activating factor (PAF)-acether antagonist BN 52021 was inactive. We conclude that bradykinin is able to attract eosinophil in vivo by a mechanism independent of PAF-acether and sensitive to the blockage of the lipoxygenase pathway.